par Lemy, Anne 
;Toungouz Nevessignsky, Michel ;Abramowicz, Daniel
Référence Nephrology, dialysis, transplantation, 25, 11, page (3480-3489)
Publication Publié, 2010-11
;Toungouz Nevessignsky, Michel ;Abramowicz, Daniel Référence Nephrology, dialysis, transplantation, 25, 11, page (3480-3489)
Publication Publié, 2010-11
Article révisé par les pairs
| Résumé : | Several desensitization strategies have been investigated for the reversal of acute antibody-mediated rejection or for the removal of preformed anti-HLA antibodies, with the aim to promote access to renal transplantation. Today, their success appears limited or incomplete. Bortezomib, a selective inhibitor of the 26S proteasome, which is largely used in the treatment of multiple myeloma, could be a novel promising desensitizing agent. Its mechanism of action and preliminary clinical use in renal transplantation is reviewed here. |
